Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470849 | 0.80 | GPR119 (0.41) | GPR119ACACBKCNH2 | |
| SCHEMBL121187 | 0.79 | GPR119 (0.49) | CHRM2CHRM1CHRM3GPR119ACACB | |
| SCHEMBL1721013 | 0.76 | GPR119 (0.49) | GPR119 | |
| SCHEMBL121128 | 0.75 | SIGMAR1 (0.39) | SIGMAR1GPR119ACACBKCNH2 | |
| SCHEMBL148369 | 0.75 | SIGMAR1 (0.39) | SIGMAR1GPR119ACACBKCNH2 | |
| SCHEMBL2556222 | 0.74 | GPR119 (0.46) | CHRM2CHRM1CHRM3GPR119KCNH2 | |
| SCHEMBL470645 | 0.72 | GPR119 (0.40) | GPR119ACACB | |
| SCHEMBL19438390 | 0.71 | GPR119 (0.43) | CHRM2CHRM1CHRM3GPR119KCNH2 | |
| SCHEMBL27846279 | 0.71 | GPR119 (0.46) | CHRM2CHRM1CHRM3GPR119KCNH2 | |
| SCHEMBL24437526 | 0.71 | GPR119 (0.48) | CHRM2CHRM1CHRM3GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |